Citius Pharmaceuticals Azioni (NASDAQ: CTXR)

Ultime notizie per Citius Pharmaceuticals (NASDAQ:CTXR) Azioni

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

Oggi alcuni titoli azionari stanno attirando particolare attenzione nel pre-market a causa di annunci chiave e movimenti significativi.

Pre-market: 5 titoli da monitorare oggi, 30 dicembre 2024

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

JMP Securities analyst Andrew Boone reiterates Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) from Market Perform to Market Perform.

Reiteration

Analyst Ratings

GOOGL

JMP Securities Reiterates Market Perform on Alphabetto Market Perform

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and raises the price target from $45 to $47.

Price Target

TVTX

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $47

ReShape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) on Wednesday signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their neuromuscular rehabilitation <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">devices in the U.S</a>.
The flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44722857/reshape-lifesciences-partners-with-motion-informatics-to-bring-ai-driven-neurorehabilitation-techn" rel="noreferrer noopener">Annual Conference and Expo</a>.
&#8220;The signing of this agreement with Motion Informatics marks a significant milestone for ReShape as we expand and diversify into rehabilitation technology,&#8221; ReShape CEO Paul F. Hickey said.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44721380/redwire-joins-ispace-us-in-pursuit-of-nasas-26b-lunar-economy-mission" rel="noreferrer noopener">Redwire Joins ispace Tech In Pursuit Of NASA&#8217;s $2.6 Billion Lunar Economy Mission</a>
Stimel-03 is FDA-cleared and commercially available. It&#8217;s a single, patient-responsive platform that helps patients recover from stroke, injury, or surgery.
&#8220;This partnership accelerates Motion Informatics&#8217; U.S. market strategy by combining ReShape Lifesciences&#8217; commercial reach with our differentiated rehabilitation technologies,&#8221; added Gary Sagiv, CEO of Motion Informatics. 
On Monday, ReShape Lifesciences announced 2024 revenue of $8 million, a contraction of 7.7%, or $700,000, compared <a href="https://www.benzinga.com/pressreleases/25/04/g44673681/reshape-lifesciences-reports-year-ended-december-31-2024-financial-results-and-provides-corporate-" target="_blank" rel="noreferrer noopener">to the same period in 2023</a>.
The primary reason for the decrease is due to the introduction of GLP-1 pharmaceuticals within the U.S.
With the introduction of Lap-Band 2.0, the company experienced a slight growth in units sold of 6.5%.
However, sales of the Lap-Band accessories units decreased by 26.4% within the U.S.
Worldwide sales of Lap-Band units decreased by 8.5%, and accessories decreased by 25.9%. The company increased the price of Lap-Band systems, including accessories, which helped revenues not decrease at the same ratio as the decline in unit sales.
Price Action: ReShapestock is up 80.1% at $0.62 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44725000/kkr-outbids-competitors-edges-closer-to-29b-karo-healthcare-takeover-report" target="_blank" rel="noreferrer noopener">KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover</a></li>
</ul>
Image: Shutterstock

Penny Stocks

Health Care

Movers

General

RSLS

Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US

Government

Regulations

Politics

White House's Miran Says Need To Get Regulations Out Of The Way So That Companies Can Build Factories Faster; President Trump's Policies Are Working At Keeping Inflation At Bay

Canaccord Genuity analyst Austin Moeller maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy and raises the price target from $14.5 to $15.5.

SPIR

Canaccord Genuity Maintains Buy on Spire Global, Raises Price Target to $15.5

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and maintains $3 price target.

PACB

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

CYTK

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

As of April 10, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On March 4, Wheeler Real Estate IT posted fourth-quarter FFO of $18.48, down from $182.82 in the year-ago period. The company's sales rose to $27.59 million from $26.21 million. The company has a 52-week high of $3,588.00.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 4.8% to close at $2.37 on Wednesday.</li>
<li>Edge Stock Ratings: 0.39 Momentum score with Value at 36.37. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/whlr"><img loading="lazy" decoding="async" width="487" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62.png" alt="" class="wp-image-865450" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62.png 487w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62-300x116.png 300w" sizes="(max-width: 487px) 100vw, 487px" /></a></figure>
<h3 class="wp-block-heading">Stratus Properties Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRS#NASDAQ">STRS</a>)</h3>
<ul>
<li>On March 28, the company said revenues for 2024 surged to $54.2 million from $17.3 million for 2023. William H. Armstrong III, Chairman of the Board of Directors (Board) and Chief Executive Officer of Stratus, stated, &#8220;Our experienced team continues to successfully execute on our disciplined strategy by delivering on value-enhancing transactions, continuing to advance our development projects and returning capital to stockholders." The company's stock gained around 23% over the past five days and <a href="https://www.benzinga.com/quote/STRS">has a 52-week high</a> of $30.66.</li>
<li>RSI Value: 75.4</li>
<li>STRS Price Action: Shares of Stratus Properties gained 18.1% to close at $20.91 on Wednesday. </li>
</ul>
How do other stocks rank? Get the full <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">BZ Edge Rankings breakdown here</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

STRS

WHLR

Top 2 Real Estate Stocks That May Keep You Up At Night This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) price target from $30 to $39. Wells Fargo analyst Jeff Cantwell upgraded the rating from Underweight to Overweight. Toast shares closed at $34.38 on Wednesday. <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim slashed the price target for Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) from $15 to $13. Guggenheim analyst Subbu Nambi maintained a Buy rating. Neogen shares closed at $5.02 on Wednesday. <a href="https://www.benzinga.com/quote/NEOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS lowered BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) price target from $38 to $31. UBS analyst Joseph Spak downgraded the stock from Buy to Neutral. BorgWarner shares closed at $26.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities cut the price target for IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) from $263 to $216. Truist Securities analyst Jailendra Singh maintained a Buy rating. IQVIA shares closed at $157.02 on Wednesday. <a href="https://www.benzinga.com/quote/IQV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $171 to $159. B of A Securities analyst Tim Anderson maintained a Neutral rating. Johnson &amp; Johnson shares closed at $150.97 on Wednesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital slashed Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) price target from $275 to $170. Loop Capital analyst Mark Schappel downgraded the stock from Buy to Hold. Manhattan Associates shares settled at $166.26 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view </a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings">this </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>Barclays cut ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) price target from $55 to $50. Barclays analyst Manav Patnaik upgraded the stock from Underweight to Equal-Weight. ManpowerGroup shares closed at $52.87 on Wednesday. <a href="https://www.benzinga.com/quote/MAN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $265 to $230. Truist Securities analyst Youssef Squali maintained a Buy rating. Amazon shares closed at $191.10 on Wednesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho cut the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $4.2 to $3.5. Mizuho analyst Vijay Rakesh maintained a Neutral rating. NIO shares settled at $3.31 on Wednesday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $208 to $185. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Alphabet shares closed at $158.71 on Wednesday. <a href="https://www.benzinga.com/quote/googl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOOGL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png" alt="" class="wp-image-865996" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

AMZN

MANH

NEOG

TOST

Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday

Contracts

SYNX

Silynxcom Secures New Purchase Order Valued At ~$1.13M From The Israel Defense Forces

Scotiabank analyst Greg McGinniss maintains Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) with a Sector Outperform and lowers the price target from $28 to $24.

COLD

Scotiabank Maintains Sector Outperform on Americold Realty Trust, Lowers Price Target to $24

Macro Economic Events

Economics

White House Economic Adviser Miran Says President Is Buying Time To Create Trade Deals; Never Thought That We Were Headed For Meaningful Recession; Need To Get Regulations Out Of The Way So That Companies Can Build Factories Faster

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)</h3>
<ul>
<li>Dividend Yield: 6.28%</li>
<li>Mizuho analyst Anthony Crowdell maintained an Outperform rating and cut the price target from $16 to $15 on March 4, 2025. This analyst has an accuracy rate of 64%.</li>
<li>B of A Securities analyst Julien Dumoulin-Smith upgraded the stock from Underperform to Neutral and raised the price target from $11 to $13 on March 4, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: The AES will host a conference call on Friday, May 2, to review its first quarter financial results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">latest AES news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="908" height="801" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63.png" alt="" class="wp-image-865471" style="width:514px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63-300x265.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63-768x677.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Avista Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>)</h3>
<ul>
<li>Dividend Yield: 4.94%</li>
<li>Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating and slashed the price target from $40 to $39 on Jan. 28, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Mizuho analyst Anthony Crowdell upgraded the stock from Underperform to Neutral and raised the price target from $32 to $36 on May 3, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: Avista will hold its quarterly conference call and webcast to discuss first quarter results on Wednesday, May 7.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest AVA <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="911" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64.png" alt="" class="wp-image-865473" style="width:599px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64-768x685.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Northwest Natural Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>)</h3>
<ul>
<li>Dividend Yield: 4.85%</li>
<li>Stifel analyst Selman Akyol maintained a Buy rating and cut the price target from $45 to $44 on Nov. 14, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Janney Montgomery Scott analyst Michael Gaugler upgraded the stock from Neutral to Buy and raised the price target from $36 to $43 on Aug. 5, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On March 3, NW Natural Holdings named Justin B. Palfreyman as new CEO.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NWN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="915" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65.png" alt="" class="wp-image-865476" style="width:495px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65-768x691.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Dividends

Wall Street's Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $18 to $20.

BNTC

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $20

ISRG

Intuitive Says FDA Clears Fully Wristed SP SureForm 45 Stapler Designed For Single-Port Robotic Surgery

WIIM

Viking Holdings shares are trading lower. Morgan Stanley cut its price target on the stock from $49 to $47.

Home furnishing brand The Lovesac Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares are <a href="https://www.benzinga.com/premarket">surging in premarket on Thursday</a>, after the fourth-quarter earnings.
The company reported a <a href="https://www.benzinga.com/pressreleases/25/04/g44730835/the-lovesac-company-reports-fourth-quarter-and-fiscal-2025-financial-results">fourth-quarter FY25 revenue decline </a>of 3.6% year-on-year to $241.490 million, beating the analyst consensus estimate of $233.954 million.
Gross profit decreased 2.6% Y/Y to $145.8 million, with the margin expanding 70 basis points to 60.4%. Total comparable sales declined 9.4%. Internet sales dropped 9.7% in the quarter.
Total operating expenses fell 10.1% Y/Y to $98.2 million. The operating income increased 17.8% to $47.6 million and the operating margin expanded 360 basis points to 19.7%.
Also Read: <a href="https://www.benzinga.com/news/25/04/44698868/tariffs-recession-fears-could-derail-wayfair-rh-and-etsy-says-analyst">Tariffs, Recession Fears Could Derail Wayfair, RH And Etsy, Says Analyst</a>
Adjusted EBITDA increased 11.4% Y/Y to $53.9 million. EPS of $2.13&nbsp;<a href="https://www.benzinga.com/earnings">topped the consensus </a>of $1.87.
As of July 30, 2023, Lovesac held $54.7 million in cash and equivalents. Net cash provided by operating activities during the quarter totaled $44 million.
&#8220;After a slow start to the holiday selling season, strong execution by our teams dramatically improved conversion of customer quotes to sales throughout the remainder of the fourth quarter. This supported a mid-teens year-over-year increase in net income for the quarter and helped close out another year of market share gains for full year Fiscal 2025,&#8221; said CEO Shawn Nelson.
Lovesac appointed Heidi Cooley as <a href="https://www.benzinga.com/pressreleases/25/04/g44730896/the-lovesac-company-appoints-heidi-cooley-as-chief-brand-and-marketing-officer">Chief Brand and Marketing Officer</a>, effective April 23, 2025. 
Outlook: For the first quarter Lovesac sees EPS of $(0.66) &#8211; $(0.85) versus the Street view of $(0.77) and sales of $136 million &#8211; $142 million against the estimate of $138.60 million.
The company expects FY26 EPS of $0.80 &#8211; $1.36 versus the estimate of $1.10 and sales of $700 million &#8211; $750 million versus the estimate of $713.05 million.
Price Action: LOVE shares traded higher by 16.38% at $18.54 in premarket at last check Thursday.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
Photo: Shutterstock

LOVE

Why Is Home Furnishing Brand Lovesac's Stock Surging Today?

BRTX

BioRestorative Therapies Confirms It Faces No Material Impact From Reciprocal Tariffs

NextNRG, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXXT#NASDAQ">NXXT</a>), a pioneer in AI-driven energy innovation—transforming how energy is produced, managed, and delivered through its advanced Utility Operating System, smart microgrid technology, wireless EV charging, and on-demand mobile fuel delivery solutions— today announced preliminary unaudited revenue and volume results for March 2025 and the first quarter of 2025. The company delivered its third consecutive record month, with March revenue increasing 161% year-over-year to approximately $6.15 million.
March 2025 Highlights
<ul>
<li>Revenue: $6,148,266 (vs. $2,354,048 in March 2024)</li>
<li>YoY Revenue Growth: 161%</li>
<li>Gallons Delivered: 1,799,955 (vs. 580,217 in March 2024)</li>
<li>YoY Gallon Growth: 210%</li>
</ul>
Q1 2025 Highlights
<ul>
<li>Revenue: $16,232,354 (vs. $6,597,119 in Q1 2024)</li>
<li>YoY Revenue Growth: 146%</li>
<li>Gallons Delivered: 4,688,045 (vs. 1,658,272 in Q1 2024)</li>
<li>YoY Gallon Growth: 183%</li>
</ul>

Earnings

Guidance

NXXT

NextNRG Reports Preliminary March 2025 Revenue Of $6,148,266 Up From $2,354,048 YoY; Q1 Revenue $16,232,354 Up From $6,597,119 YoY

United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares are facing selling pressure on Thursday after President Donald Trump suggested he doesn't want to see the company get <a href="https://www.benzinga.com/markets/commodities/25/04/44679320/us-steel-gains-16-as-trump-orders-review-of-nippon-steels-blocked-acquisition-amid-national-security-concerns" target="_blank" rel="noreferrer noopener">acquired by Nippon Steel</a>.
What To Know: In a <a href="https://www.youtube.com/watch?v=qr9AeMFXzpY" target="_blank" rel="noreferrer noopener">press conference</a> from the Oval Office after the market close on Wednesday, Trump told reporters he wants U.S. Steel to remain a U.S. company. 
"We don't want to see it go to Japan. You know, we love Japan, but U.S. Steel is a very special company," Trump said.
U.S. Steel and Nippon Steel filed lawsuits in January after the Biden administration blocked Nippon&#8217;s proposed $14.9-billion acquisition of U.S. Steel, originally announced at the end of 2023. The companies claimed &#8220;wrongful interference&#8221; with the planned takeover deal. 
The Biden administration said last year that it was <a href="https://www.benzinga.com/news/24/07/39613777/amid-opposition-from-biden-and-workers-nippon-steel-vc-returns-to-discuss-us-steel-acquisition" target="_blank" rel="noreferrer noopener">"vital"</a> that U.S. Steel remained a domestically operated American steel company. The proposed acquisition had become a major topic of discussion leading up to the presidential election in November.
U.S. Steel shares surged earlier this week after Trump ordered a <a href="https://www.benzinga.com/markets/commodities/25/04/44679320/us-steel-gains-16-as-trump-orders-review-of-nippon-steels-blocked-acquisition-amid-national-security-concerns" target="_blank" rel="noreferrer noopener">national security review</a> of the company's blocked deal with Nippon Steel. The stock reversed course following Trump&#8217;s comments late Wednesday. 
"If you go back to U.S. Steel from 90 years ago, it&#8217;s incredible. It was the number one company in the world for a long time. That's why we don't want to see it go to Japan,&#8221; Trump said. 
X Price Action: <a href="http://benzinga.com/quote/X" target="_blank" rel="noreferrer noopener">U.S. Steel shares</a> were down 11.6% at $39.91 at the time of publication Thursday morning, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/saweangw">saweang.w</a>/Shutterstock.

US Steel Stock Is Falling Thursday: What's Going On?

Offerings

Press Releases

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Stock Split

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

CTOR

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Athira Pharma

Aytu BioPharma

Biofrontera

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals

Durect

Gelteq

Hoth Therapeutics

Impact BioMedical

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Talphera

Traws Pharma

TherapeuticsMD

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Comments

Citius Pharmaceuticals

Notizie

Ultime notizie per Citius Pharmaceuticals (NASDAQ:CTXR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO